Vancouver, British Columbia–(Newsfile Corp. – September 29, 2020) – Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant“) or (the “Company“) is pleased to announce that its majority owned subsidiary NeonMind Biosciences (“NeonMind“) has entered into a definitive agreement with Psygen Labs Inc. (“Psygen“) for the supply of psilocybin for NeonMind’s planned preclinical, and clinical trials to study the use of a drug product including Psilocybin for the treatment of food cravings and anxiety. The agreement was signed on September 28th, 2020.
Figure 1: Better Plant Sciences Subsidiary NeonMind Signs Psilocybin Supply Agreement for Clinical Trials
To view an enhanced version of Figure 1, please visit:
Psygen is currently acting as broker between NeonMind and a licensed dealer of restricted drugs (the “Licensed Dealer“). The Licensed Dealer holds a dealer’s licence issued under Part J of the Food and Drug Regulations (a “Dealer’s Licence“). The Supply Agreement provides that Psygen will supply the psilocybin directly once Psygen holds a Dealer’s Licence. Psygen currently has a pending application for a Dealer’s Licence.
“Psilocybin is known to activate serotonin receptors,” says Dr. William Panenka, lead scientific advisor to NeonMind. “As a neurotransmitter, serotonin helps to relay messages from one area of the brain to another. Serotonin is responsible for some of the drivers which govern eating. We are very interested in furthering studies to test various dosing regimens for NeonMind to see the effects that psilocybin may have on the serotonin receptors that regulate food cravings.”
“Psygen’s mission is to fill a supply gap for restricted drug substances and restricted drug products for use in clinical trials and in pre-clinical research,” says Danny Motyka, CEO of Psygen Labs Inc. “We have brokered supply of various restricted drugs for pre-clinical studies and clinical trials through our relationship with a Licensed Dealer. Psygen is currently building out a commercial manufacturing facility designed for high-volume output of psychedelic drug substances and drug products, filling a niche in the evolving psychedelic medicine ecosystem. Today these psychedelic drug substances are classified as restricted drugs, meaning no recognized medical use in Canada, and we are playing our part in moving those substances to the controlled drugs schedule of the Food and Drug Regulations or otherwise providing compliant access to psilocybin and other psychedelics.”
In December 2019, NeonMind filed a U.S. provisional patent application in the United States for the invention relating to therapeutic administration of psilocybin to provide weight loss benefits and potential treatment or regulation of diabetes, and regulation of blood glucose, and to reduce susceptibility to cardiovascular disease, high blood pressure, diabetes mellitus, hypertension, multiple sclerosis, erectile dysfunction, urinary incontinence, chronic renal failure, sleep apnea, asthma, and certain forms of cancer.
In May 2020, NeonMind completed the design of a preclinical trial to confirm that psilocybin is an effective treatment for weight loss and food cravings (the “Trial“). In July 2020, the scientific investigator chosen to lead NeonMind’s preclinical trial submitted a Section 56 Exemption application to Health Canada for the use of psilocybin in the Trial. An exemption must be granted and a final agreement entered into with the laboratory before the Trial can begin.
According to the World Health Organization, in 2016, more than 1.9 billion adults or 39% of adults, 18 years and older, were overweight. Grandview Research projects that the global weight management market is expected to grow at a compound annual growth rate of 8.3% from 2019 to 2025 to reach USD $442.3 billion by 2025.
About Psygen Labs Inc.
Psygen is a privately held company based in Calgary, Alberta. Psygen specializes in synthetic manufacture of psychedelic drug substances and drug products. Psygen provides non-exclusive access to GMP compliant psychedelic drug substances and drug products for clinical trials, therapeutic applications and pre-clinical studies. Psygen has entered into a number of definitive agreements for ongoing supply of drug substances and is positioned to be a lead supplier in the emerging commercial market for psychedelic drug substances and drug products. Psygen has sponsored a Licensed Dealer who holds a license for the manufacture, sale, import, export, and analysis of LSD, psilocybin, MDMA, DMT, 2C-B, and mescaline. Chemists working with Psygen currently operate from a manufacturing laboratory at the University of Alberta. Psygen has applied to Health Canada for a Dealer’s License that will allow Psygen to manufacture, possess, sell, import, export, research, develop, and analyze psychedelic drug substances and drug products. Psygen is currently building out a 6,000 square foot lab capable of large-scale synthesis, formulation and distribution of the above and additional psychedelics to a GMP standard. Psygen intends to be the leader in psychedelic medicine supply chain solutions and is committed to supporting the renaissance in use of psychedelics for research and clinical treatment of a wide variety of mental health issues.
About NeonMind Biosciences Inc.
NeonMind is engaged in research and development of products that use medicinal and psychedelic mushrooms to optimize human health and performance. The company is launching a line of coffees infused with health optimizing medicinal mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for a Section 56 Exemption to begin preclinical trials to study its pending psychedelic medicine patents. NeonMind owns 18% of Translational Life Sciences Inc. Better Plant Sciences owns approximately 69% of the issued and outstanding stock of NeonMind.
About Better Plant Sciences Inc.
Better Plant develops and acquires intellectual property and other assets related to plant-based products and therapeutics. Through its integrated business model, Better Plant develops, manufactures, markets, sells and distributes plant-based products. It has over 200 proprietary wellness formulas at various stages of commercialization, including over 20 proprietary products that are now for sale via eCommerce or brick-and-mortar retail stores. It operates websites and oversees eCommerce and Amazon sales for over 200 JUSU plant based products for body, baby and home and has announced it will acquire all JUSU Bar Inc. assets. Its majority-owned subsidiary NeonMind Biosciences Inc. is launching a line of coffees infused with health optimizing medicinal mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for a Section 56 Exemption to begin preclinical trials to study its pending psychedelic medicine patents.
Investor Relations Contact:
Penny White, President & CEO
Kevan Matheson, Investor Relations
The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of the Coronavirus, the potential for not acquiring any rights as a result of the patent application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen. Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64798
PURA 1-for-1 Shareholder Dividend of PAOG Shares on Track
Dallas, Texas–(Newsfile Corp. – October 30, 2020) – PAO Group, Inc. (OTC Pink: PAOG) and Puration, Inc. (OTC: Pink: PURA) today released an update on the process underway for PAOG to issue PAOG shares to PURA shareholders in a dividend distribution.
PAOG acquired a cannabis cultivation operation from PURA earlier this year in a transaction that includes issuing PAOG shares to PURA shareholders. The target distribution ratio calls for PURA shareholders receiving one share of PAOG for every one share of PURA owned.
PAOG has executed two acquisitions in recent months and managed to ramp up and organize acquired cannabis pharmaceutical research assets as necessary to execute a contract prerequisite to developing its acquired cannabis pharmaceutical research assets into an FDA approved drug. PAOG admits the dividend distribution process has lagged behind the acquisition and pharmaceutical development contract efforts. Last week, after completing the pharmaceutical development contract, PAOG management and PURA management committed to rapidly completing the dividend issuance.
Since initiating the joint rapid dividend completion effort, PAOG has filed to redomicile the company to Wyoming and increase the authorized number of shares in order to have the necessary inventory to execute the dividend distribution. PAOG has also engaged the services of the company’s transfer agent to manage the dividend distribution of PAOG stock to PURA shareholders. Once the move to Wyoming is complete, PAOG will file with the necessary financial regulatory authority to finalize the dividend details. PAOG anticipates a definitive dividend distribution announcement will be forthcoming within the next two weeks.
PAOG is excited to make PURA shareholders also PAOG shareholders.
The developing PAOG and PURA partnership includes PAOG participating in PURA’s new hemp lifestyle brand strategy, called Farmersville Brands and headquartered on a 72-acre property currently under contract for acquisition by PURA. In conjunction with PAOG’s newly acquired cultivation business, PAOG plans to build a pharmaceutical grade, indoor hemp cultivation operation and lab on PURA’s Farmersville property.
Look for more information coming soon from both PURA and PAOG.
For more information on PAO Group, visit www.paogroupinc.com.
For more information on Puration, visit www.purationinc.com.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
PAO Group, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67197
Early Warning Report in Connection with the Sale of 5,500,000 Subordinate Voting Shares of Green Thumb Industries Inc.
Chicago, Illinois–(Newsfile Corp. – October 30, 2020) – On October 29, 2020, RCP23, LLC (the “Seller”), a private investment holding company controlled by Benjamin Kovler, CEO and Chairman of Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) (the “Issuer”), sold 5,500,000 Subordinate Voting Shares of the Issuer (the “Transferred Shares”) to a third-party qualified institutional buyer at a purchase price of C$19.25 per share in a private transaction. Prior to the sale, at Seller’s request, the Issuer converted 54,805 Super Voting Shares and 49,448 Multiple Voting Shares of the Issuer previously held by the Seller into an aggregate 10,425,300 Subordinate Voting Shares per the terms of the Issuer’s Articles of Incorporation, as amended.
Following the sale, Mr. Kovler, together with his joint actors, holds beneficial ownership or control or direction over 183,254 Super Voting Shares, which represent 56.5% of the class, 0 Multiple Voting Shares, and 5,068,016 Subordinate Voting Shares, which represent less than 2.9% of the class. Each Super Voting Share carries 1,000 votes and is convertible into one Multiple Voting Share and each Multiple Voting Share carries 100 votes and is convertible into 100 Subordinate Voting Shares (each of which carries one vote).
For further information, please contact Investor Relations, Green Thumb Industries Inc., InvestorRelations@GTIgrows.com, Phone: 310-622-8257.
This press release is issued pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, which requires an early warning report to be filed on SEDAR (www.sedar.com) containing additional information with respect to the foregoing matters. A copy of this report may be obtained by contacting Investor Relations, Green Thumb Industries Inc., InvestorRelations@GTIgrows.com, Phone: 310-622-8257.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67179
Special Guests and Lovers of Psychedelics Are “Coming Out of the Chemical Closet” to Celebrate New Book about MDMA — Register For Virtual Book Launch
New York, New York–(Newsfile Corp. – October 30, 2020) – Charley Wininger and his publisher Inner Traditions are welcoming the arrival of his book “Listening to Ecstasy: The Transformative Power of MDMA” with a free virtual night of storytelling on Nov 13th, 7:00 PM (Eastern Time). Members of the press are invited to join this unique event. To register click link HERE.
To view an enhanced version of this graphic, please visit:
Charley will be joined by several psychedelic luminaries, and hosted by comedian Sarah Rose Siskind. They will share intimate, touching and humorous stories about a time their lives were transformed by the often misunderstood underground party drug, MDMA.
In his book, “Listening to Ecstasy” Charley reveals how MDMA has enhanced his marriage both erotically and emotionally, and describes how pleasure, fun, and joy can be profound bonding and transformative experiences.
To view an enhanced version of this graphic, please visit:
“This is also the story of how my wife and I entered a forbidden world of drug users, and found it to be enchanted. MDMA opened up our lives to new friends, fun, and freedom. It’s also helped us navigate the aging process as we transitioned from middle age into our sixties and seventies.” – Charley Wininger
Wininger’s writing and personal narrative shows how MDMA can be a tool for healing and connection. This is why this particular psychedelic compound is being studied to treat Post-Traumatic Stress Disorder (PTSD) with Phase 3, peer-reviewed trials taking place at research sites in the U.S., Canada, and Israel. (Multidisciplinary Association for Psychedelic Studies, 2020). At the current pace, MDMA will be a prescription medication in the U.S. by 2023.
In a recent Forbes article, Charley referred to MDMA as “super glue for relationships“. He and his wife are open to giving candid interviews about how MDMA helps to strengthen their connection.“It can help you connect with yourself, with your loved ones and with the world at large, [which] is especially important now when we live in a time of isolation and fear.” – Charley Wininger (Forbes)
Members of the media
- Check out the Charley Wininger Media Kit for quotes and downloadable images
- Book interview with Charley before launch (Nov. 13th)
- Request media review copy of Listening to Ecstasy
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67182
Cannabis3 weeks ago
Bud & Tender® raise testing and quality standards for best CBD oil in the UK
Cannabis3 weeks ago
The World’s Greatest Weight Loss Secret May be Psilocybin
Cannabis2 weeks ago
Aither Ingredients Announces Joint Venture With Thar Process Intended to Disrupt the Canadian Cannabis-based Ingredient Market
Cannabis4 weeks ago
WeedMD Reports Second Quarter 2020 Financial Results and Closes $30 Million Credit Facility with LiUNA Pension Fund
Cannabis4 weeks ago
PAOG Engages Saul Kaye, Founder of iCAN: Israel-Cannabis and CannaTech to Prepare RespRx for IND
Cannabis2 weeks ago
IGNITE Files Q2 2020 Financial Statements and MD&A
Cannabis3 weeks ago
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 (COVID-19)
Cannabis2 weeks ago
Next Green Wave Sauce Carts Sell Over 100k In Under 30 Days